Late Breaking Abstracts Submission Guidelines

March 18, 2024

Initial Submission Requirements

  • All abstracts must be submitted via the online submission site.  Submissions will not be accepted via other means, i.e. email, fax, postal mail, etc. 
  • A non-refundable abstract handling fee of $150.00 USD is due at the time of abstract submission (credit cards are accepted). If you need to pay with a method other than a credit card, please email [email protected]. Abstract submission does not automatically register you for ENDO. Upon submission, the presenting author of the abstract agrees to register and attend ENDO to present the abstract. If the presenter is unable to attend, a co-author may register for the meeting and present in their place.  If the presenting author or appropriate co-author fails to register and present the abstract at ENDO, the submission will be considered withdrawn from ENDO and the abstract will not be published in Endocrine Society journals and publications.
  • The abstract character limit is 2,500 characters, including punctuation and symbols, but not spaces.
  • Membership is not a requirement to submit an abstract for ENDO.  Submitters are encouraged to include at least one author on their submission who is a member of the Society. Membership status has no impact on peer review decisions if accepted for presentation.
    • Endocrine Society members receive special discounted ENDO registration rates. Additionally, only Endocrine Society members will be considered for abstract awards. Join now to get the best rate for ENDO.
  • Abstracts must have a submission status of COMPLETE by Wednesday April 10, 2024.  An abstract is not considered complete until all required information has been submitted and the abstract handling fee has been paid.  Requests to submit abstracts beyond the stated deadline will not be considered. 
  • Authors are not limited on the number of abstracts that they submit.  If an author appears on more than one accepted abstract as presenting author, they are responsible for resolving any conflicts that arise if they have multiple submissions scheduled to be presented at the same time.  
  • Abstracts must be submitted in English.

Report original information.

  • At the time of submission, the study/clinical case report should contain unpublished information.  The abstract should not include any previously published verbatim information/text as a scientific article or meeting abstract. The abstract submitted for ENDO 2024 must contain novel and original scientific data and information to reflect ongoing progress. Review the abstract embargo policy.
  • The submission must include endocrine-related information.
  • The Endocrine Society welcomes industry submissions containing endocrine research, scientific data, and results. Abstracts deemed to contain commercial content, commercial products, or service-related advertisements or opinions lacking rigorous scientific data may be rejected.

Literature reviews

  • Reviews may only be submitted if they are a systemic review, with or without meta-analysis. A meta-analysis is acceptable in the scientific themes as long as it provides new data-driven conclusions.  Abstracts should make this point clearly. Reviews must critically discuss results.

Submissions must include data and summarize efforts to ensure rigor.

  • Scientific rigor is the structured and controlled application of the scientific method using the highest standards in the field, including considerations in experimental design, data analysis, and reproducibility. Abstracts that state that “results will be discussed” will be rejected.
  • Abstracts of studies need to present the research question, rationale, and whether the study is exploratory or confirmatory. Abstracts that state that “results will be discussed” will be rejected.
  • To ensure scientific rigor, presenters are expected to transparently report a study’s experimental design and analytical methods in their presentation. When relevant, state the sex of experimental subjects and whether sex differences were assessed.
  • State efforts to ensure scientific rigor and reduce bias, including blinding, statistics, sample sizes, and replication. Describe the controls used for the studies. 
  • Note biological variables such as species, sex, age, strain, or cell line, when applicable.
  • Present sufficient raw data for others to judge the quality of experiments. Define error bars when used.

Guidance for Clinical Trials

  • The Society understands that limited data may be available at the time of the submission deadline. The abstract submission should detail the trial design and rationale, inclusion criteria, primary clinical endpoints, and any available preliminary data. Lead investigators are still encouraged to submit if additional data is anticipated to be available for presentation by the first day of ENDO.

Guidance for Case Reports

  • A Case Report abstract should provide valuable teaching points or learning lessons. Case Report abstracts are typically accepted as poster presentations (sometimes as oral presentations). Case Report abstracts that do not provide meaningful teaching points will not be accepted.

Submitters must confirm the contributions and roles of all participating authors.

  • The submitting author is responsible for ensuring that each author has legitimately contributed to the study, guaranteeing the final version of the abstract and that each author is aware of the submission and that their consent has been obtained to appear in annual meeting informational and promotional materials.  For more information on abstract author requirements, review the Author Agreement and License to Publish. Unauthorized use of other authors’ names without their consent is grounds for rejection.

Disclose any and all real or perceived financial relationships.

  • In general, disclosure is required when an individual or company stands to benefit financially from research performed. The central criterion of this policy places the onus for disclosure on each author to indicate any benefit to an individual or company that may derive from any and all relationships that have the potential to lead to financial gain. Any potential for financial gain derived from reported work might constitute a conflict of interest. Authors should clearly acknowledge financial contributions from commercial sponsors to the work being reported, which might be perceived as conflicts of interest (see III.2). Authors should ensure that no contractual relations or proprietary considerations restrict dissemination of their findings. It is the author's responsibility to report any real or perceived financial relationships. Relevant financial relationships are noted next to the published abstract directing readers to relevant financial relationships listed in the Program.

Material included in the presentation of the abstract must be substantively identical to that described in the abstract/case report.

  • The title, authorship, and scientific content of the presentation at the Endocrine Society event must substantively match that in the abstract. Significant variance will result in the presentation being considered withdrawn and the abstract not being published in any Endocrine Society journal or other publication.
Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.